Benza RL, et al. - Researchers report an update of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk calculator (REVEAL 2.0) as well as performed comparison of it with recently published European Society of Cardiology/Respiratory Society guideline-derived strategies for assessment of risk status in pulmonary arterial hypertension. They performed this study using a subpopulation from REVEAL that survived ≥ 1 year after enrollment (baseline for this cohort). Compared with the original calculator, similar discrimination was shown by REVEAL 2.0, which not only offered excellent separation of risk among the risk categories but also enabled the prediction of clinical worsening as well as mortality in patients who were observed ≥ 1 year. In patients enrolled in REVEAL, greater risk discrimination was shown by REVEAL 2.0 as compared with the COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) and FPHR (French Pulmonary Hypertension Registry) risk assessment strategies.